
Progressive Chicago mayor advocates for new 1% grocery tax to help billion-dollar deficit
Johnson's budget team met with the Committee on Finance: Subcommittee on Revenue to discuss the impending end to Illinois' grocery tax, which will expire on January 1, 2026. The city currently has until October 1 to pass a new tax to replace the expired one to maintain revenue continuity.
During the meeting, Budget Director Annette Guzman argued in favor of the new tax, warning that the city could see an increase in its deficit and services cut without it.
"Allowing that tax to lapse in 2026 would cost the corporate fund an estimated $80 million next year alone, further exacerbating our $1 billion-plus gap," Guzman said. "Nearly 200 other municipalities in Illinois — from Berwyn to Wheaton and beyond — have already voted to extend this grocery tax... If we fail to do the same, we will leave critical services on the chopping block."
She pointed to the city's police department as a potential victim of budget cuts if taxes like this were not passed.
"Roughly one-third of our corporate fund supports the police department and its related pension obligations. Without new revenue, staffing, training and community-based programs could face cuts," Guzman said.
In a press briefing, Johnson advocated for the 1% increase by pointing out that the new tax would only replace the one currently in effect without adding additional taxes.
"The City of Chicago will not enact its own grocery tax. The grocery tax already exists. There is a process in which the collection of the grocery tax is now being placed in the responsibility of municipalities," Johnson said on Tuesday. "We're not creating a grocery tax. We're just creating a process by which we can collect it."
The city council has not yet voted on a replacement tax. Alderman Andre Vasquez pointed out during the meeting that a local tax was not included in Johnson's 2025 budget, which now puts the council in an awkward position.
"Had it been included in the budget, it might have gotten done in a way that's going to feel a lot easier than this year," Vasquez said. "Hearing that 200 municipalities that already did it — it's a bit frustrating. It was a missed opportunity."
Fox News Digital reached out to members of the committee for additional comment but did not immediately receive a response.
Though the city council can pass a new tax increase after the October deadline, the City Council Office of Financial Analysis reported in May that collections on any new ordinances would not go into effect until mid-2026.
Hashtags

Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles


Fox News
a few seconds ago
- Fox News
Congressional Democrats crafting legislation to hike the salaries of public school teachers
Fox News senior congressional correspondent Chad Pergram reports on the debate over an increase in teacher salaries on 'Fox Report.'


Fox News
a few seconds ago
- Fox News
'The View' co-host Alyssa Farah Griffin slams Kamala Harris interview with Colbert
"The View" co-host Alyssa Farah Griffin slammed former VP Kamala Harris' interview with Stephen Colbert, calling it a "microcosm of everything that's wrong with Democrats post-election."
Yahoo
28 minutes ago
- Yahoo
Option Care Health, Inc. (OPCH): A Bull Case Theory
We came across a bullish thesis on Option Care Health, Inc. on Brian's Substack by Brian Flasker. In this article, we will summarize the bulls' thesis on OPCH. Option Care Health, Inc.'s share was trading at $29.35 as of July 31st. OPCH's trailing and forward P/E were 23.29 and 19.65, respectively according to Yahoo Finance. A home infusion nurse in full PPE gown delivering treatments to a patient in their own home. Option Care Health (OPCH) has evolved into the dominant independent provider of home and alternate site infusion services in the U.S., originating from Madison Dearborn Partners' 2015 acquisition of Walgreens Infusion Services. The 2019 reverse merger with BioScrip and full divestiture by Walgreens and MDP by 2023 paved the way for OPCH to operate with full independence. Led by CEO John Rademacher and CFO Michael Shapiro, both with substantial equity stakes, OPCH has built a national infrastructure of 91 pharmacies and 99 infusion suites, covering 96% of the U.S. population. The company's integrated model provides cost-effective, high-quality infusion therapies in outpatient and home settings, capitalizing on a healthcare trend shifting treatments away from costly hospitals. This platform serves over 1,400 contracts with 800+ partners, including all top 10 national insurers. Acute therapies, though operationally complex, act as a competitive wedge, while chronic therapies anchor long-term recurring revenues. OPCH's mix—75% chronic, 25% acute—combined with a focus on generics and biosimilars, ensures resilience against pricing volatility. With its Advanced Practitioner (AP) model, OPCH is pushing clinical boundaries, managing more complex therapies in lower-cost settings and enhancing utilization of its already-built infrastructure. Only ~50% of its infusion suite capacity is currently utilized, leaving ample runway for capital-light growth. Despite industry concerns like drug pricing reforms and labor shortages, OPCH's embedded relationships, clinical capabilities, and scalable model offer strong visibility into cash flow and earnings. Trading at ~15.4x 2025 owner earnings with a 17.4% expected IRR, OPCH represents a high-quality compounder with an entrenched moat and significant upside. Previously, we covered a bullish thesis on Chemed Corporation by 310 Value in April 2025, which highlighted the durability of its earnings, temporary volatility in its subsidiaries, and disciplined share repurchases. The company's stock price has depreciated by approximately 29% since our coverage. This is because temporary segment headwinds persisted longer than expected. The thesis still stands as Chemed's core fundamentals remain intact. Brian Flasker shares a similar view but emphasizes OPCH's capital-light model and payer-aligned infrastructure. Option Care Health, Inc. is not on our list of the 30 Most Popular Stocks Among Hedge Funds. As per our database, 40 hedge fund portfolios held OPCH at the end of the first quarter, which was 40 in the previous quarter. While we acknowledge the potential of OPCH as an investment, we believe certain AI stocks offer greater upside potential and carry less downside risk. If you're looking for an extremely undervalued AI stock that also stands to benefit significantly from Trump-era tariffs and the onshoring trend, see our free report on the best short-term AI stock. READ NEXT: 8 Best Wide Moat Stocks to Buy Now and 30 Most Important AI Stocks According to BlackRock. Disclosure: None. Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data